News

Press Releases

Asuragen CEO to Speak at 2017 World CDx Summit
Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio for Monitoring Molecular Response in Chronic Myeloid Leukemia
Asuragen Strengthens Repetitive Sequence and Short Structural Variant Intellectual Property Portfolio
Asuragen Launches the AmplideX® PCR/CE TOMM40 Kit1 Expanding Portfolio into the Alzheimer’s and Cognitive Impairment Space
Asuragen and Thermo Fisher Scientific to Collaborate on Diagnostic Kits for 3500 Dx Series Genetic Analyzer
Asuragen to Present at 2016 Association for Molecular Pathology Annual Meeting
Asuragen Launches QuantideX® NGS RNA Lung Cancer Kit (RUO)
Asuragen Develops Armored RNA Quant® Zika Virus Control
Asuragen’s QuantideX® qPCR BCR-ABL IS Kit Receives FDA Premarket Clearance for Monitoring Minimal Residual Disease in Chronic Myeloid Leukemia
Asuragen Launches the AmplideX® PCR/CE C9orf72 Kit for High-Resolution Genotyping of GC-rich Repeat Expansions Relevant to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

About

Back To
Top

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close